|
5HTTLPR/rs25531
| | | |
|
Wang et al. [58]
|
PTSD
|
N = 35
|
12wk prolonged exposure therapy or 12 wk Escitalopram (N = 20)
|
No significant association with treatment response in exposure therapy group
|
|
Bryant et al. [56]
|
PTSD
|
N = 45, Caucasian,
|
8 × 90 min weekly individual CBT
|
No significant association at post-treatment. At 6mth follow-up, higher % of Si allele than L allele carriers met PTSD criteria and had significantly higher symptom scores
|
|
Mage = ~ 43 yrs, 33% female
|
|
Lonsdorf et al. [59]
|
PD ± AG
|
N = 69, Caucasian,
|
10 × 2 hr weekly group (N = 38) or internet-delivered (N = 31) CBT
|
No significant association with treatment response
|
|
Mage = ~ 35 yrs, 62% female
|
|
Furmark et al. [60]
|
SAD
|
N = 204, Mage = 38 yrs,
|
9 wk internet delivered CBT or waitlist control
|
No significant association with treatment response
|
|
60% female
|
|
Kohen et al. [61]
|
DEP (post- stroke)
|
N = 61, mixed ethnicity
|
9 × positive problem solving plus antidepressant vs. usual care plus antidepressant
|
SS and SL carriers had a significantly greater mean percentage reduction in depression ratings and more likely to be in remission at 9-week follow-up than those in the control group
|
|
Sakolsky et al. [62]
|
SEP; GAD; SAD
|
N = 211, Caucasian,
|
Sertraline, 14 sessions of CBT, combination therapy or 12 wk placebo
|
No significant association with treatment response
|
|
7-17 yrs,
|
|
Eley et al. [10]
|
ANX
|
N = 359, Caucasian,
|
10-12 session group or individual CBT or guided self-help
|
No significant association at post treatment. At follow-up, higher % of SS genotype carriers free of anxiety diagnoses than SL/LL genotype carriers. SS genotype carriers had significantly greater reduction in symptom severity scores
|
|
Mage = 9.44 yrs, 49% female
|
|
Hedman et al. [63]
|
SAD
|
N = 126, 98% Caucasian, Mage = ~ 35 yrs, 36% female
|
15 × 2.5 hr weekly group (N = 62) or internet-delivered (N = 64) CBT
|
No significant association with treatment response
|
|
Bockting et al. [64]
|
Recurrent DEP
|
N = 180, Caucasian,
|
Brief CBT vs. treatment as usual
|
No significant association with time to recurrence
|
|
Mage = 45 yrs, 74% female
|
|
STin2 VNTR
| | | |
|
Kohen et al. [61]
|
DEP (post- stroke)
|
N = 64, mixed ethnicity
|
9 × positive problem solving plus antidepressant vs. usual care plus antidepressant
|
9/12 and 12/12 genotype carriers in intervention group had a significantly greater mean percentage reduction in depression scores and greater likelihood of remission at 9 wk follow-up than controls
|
|
Sakolsky et al. [62]
|
SEP; GAD; SAD
|
N = 211, Caucasian,
|
Sertraline, 14 sessions of CBT, combination therapy or 12 wk placebo
|
At 12-week assessment STin2 12-copy variant carriers showed significantly greater improvement.
|
|
7-17 yrs
|
|
HTR2A rs7997012
| | | |
|
Kotte et al. [65]
|
DEP
|
N = 58, 100% male
|
16-wk group CBT
|
G allele predicted significantly larger reduction in BDI scores across treatment compared to A allele carriers
|
|
TPH2 G-703T
| | | |
|
Furmark et al. [60]
|
SAD
|
N = 204, Mage = 38 yrs,
|
9 wk internet delivered CBT or waitlist control
|
In the CBT group, a better treatment response was observed in TPH2 GG homozygotes relative to T allele carriers
|
|
60% female
|
|
MAOA-u VNTR
| | | |
|
Reif et al. [66]
|
PD + AG
|
N = 288, Caucasian
|
12 × twice weekly CBT
|
Carriers of the long, higher activity alleleii had significantly worse treatment outcome, elevated heart rate, greater fear and panic attacks during a behavioral avoidance task and failure to habituate during repetitive exposure
|
|
COMT val158met
| | | |
|
Lonsdorf et al. [59]
|
PD ± AG
|
N = 69, Caucasian,
|
10 × 2 hr weekly group (N = 38) or internet-delivered (N = 31) CBT
|
No significant effect of COMTval158met genotype on change in anxiety or depression scores across cognitive modules (weeks 1-3). met/met genotype carriers had significantly smaller reduction in anxiety scores across exposure modules (weeks 4-9) compared to val-carriers
|
|
Mage = ~ 35 yrs, 62% female
|
|
Hedman et al. [63]
|
SAD
|
N = 126, 98% Caucasian, Mage = ~ 35 yrs, 36% female
|
15 × 2.5 hr weekly group (N = 62) or internet-delivered (N = 64) CBT
|
No significant association with treatment response
|
|
NGF rs6330
| | | |
|
Lester et al. [57]
|
ANX
|
N =374, Caucasian,
|
10-12 session group or individual CBT or guided self-help
|
No significant association with treatment response at post treatment. At follow-up, children with one or more copies of T allele of NGF rs6330 were significantly more likely to be free of anxiety diagnosis
|
|
Mage = 9.46 yrs, 49% female
|
|
BDNF val66met; rs7934165; rs1519480; rs11030104
| | |
|
Sakolsky et al. [67]
|
SEP; GAD; SAD
|
N = 211, Caucasian,
|
Sertraline, 14 sessions of CBT, combination therapy or 12 wk placebo
|
No significant association with treatment response
|
|
7-17 yrs
|
|
Lester et al. [57]
|
ANX
|
N = 374, Caucasian,
|
10-12 session group or individual CBT or guided self-help
|
No significant association with treatment response
|
|
Mage = 9.46 yrs, 49% female
|
|
Hedman et al. [63]
|
SAD
|
N = 126, 98% Caucasian, Mage = ~ 35 yrs, 36% female
|
15 × 2.5 hr weekly group (N = 62) or internet-delivered (N = 64) CBT
|
No significant association with treatment response
|
|
Fullana et al. [68]
|
OCD
|
N = 106, Caucasian,
|
20 × 45 min weekly exposure based CBT plus SSRI
|
Met allele carriers significantly less likely to respond to treatment than non-met allele carriers. Genotype predicted response only and not change in severity scores
|
|
Mage = 33 yrs, 50% female
|
|
GRIN2B rs1019385
| | | |
|
Sakolsky et al. [67]
|
SEP; GAD; SAD
|
N = 211, Caucasian,
|
Sertraline, 14 sessions of CBT, combination therapy or 12 wk placebo
|
No significant association with treatment response
|
|
7-17 yrs
|
|
GRIK4 rs1954787
| | | |
|
Sakolsky et al. [67]
|
SEP; GAD; SAD
|
N = 211, Caucasian,
|
Sertraline, 14 sessions of CBT, combination therapy or 12 wk placebo
|
Significant association with treatment response at 12 week assessment
|
| | |
7-17 yrs
| | |